A Phase 3, Open-label, Randomized, Multicenter, 12 Months, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin - Therapy in Pre-pubertal Children With Growth Hormone Deficiency
Phase of Trial: Phase III
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Somatrogon (Primary)
- Indications Somatotropin deficiency
- Focus Registrational; Therapeutic Use
- Sponsors OPKO Health
- 18 Dec 2017 Planned primary completion date changed from 1 Feb 2019 to 1 Jun 2019.
- 10 Jun 2017 Biomarkers information updated
- 30 Dec 2016 Status changed from not yet recruiting to recruiting, according to an OPKO Health media release.